This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Acetazolamide's Headache Inducing Characteristics and Effects on the Cerebral Arteries and Blood Flow

This study has been completed.
Information provided by (Responsible Party):
Nanna Arngrim, Danish Headache Center Identifier:
First received: December 11, 2012
Last updated: July 8, 2013
Last verified: July 2013
In this study the investigators will research the hypothesis that the drug Acetazolamide induce headache and dilation of cerebral arteries and increase the cerebral blood flow in the areas of the brain supplied by these arteries.

Condition Intervention
Headache Migraine Drug: Acetazolamide

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: Basic Research on Acetazolamide´s Headache Inducing Characteristics and Effects on the Cerebral Arteries and Blood Flow in a Humane Experimental Headache Model

Resource links provided by NLM:

Further study details as provided by Nanna Arngrim, Danish Headache Center:

Primary Outcome Measures:
  • Headache scores [ Time Frame: 24 h ]
    Comparison between Acetazolamide and placebo (saline).

Secondary Outcome Measures:
  • Artery circumference [ Time Frame: Baseline, 30 min and 60 min ]
    Acetazolamide induced changes in intracranial artery circumference before and after infusions.

  • Cerebral blood flow [ Time Frame: Baseline, 30 and 60 min. ]
    Acetazolamide induced changes in cerebral blood flow.

Enrollment: 12
Study Start Date: December 2012
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Acetazolamide
Acetazolamide 1 g in 10 ml saline, i.v. infusion
Drug: Acetazolamide
1 g diluted in 10 ml saline, i.v. bolus injection.
Other Name: Diamox
Placebo Comparator: Saline
Saline, 10 ml i.v. infusion

Detailed Description:

To investigate headache score and accompanying symptoms during and after infusion of acetazolamide.

With magnetic resonance imaging the investigators will investigate changes in regional cerebral blood flow (rCBF) in the area supplied by middle cerebral artery (MCA), diameter of MCA, the Internal carotic artery (ICA), the superficial temporal artery (STA) and the Medial Meningeal artery (MMA).


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy volunteers
  • Aged 18-40
  • 50-100 kg
  • Fertile women must use safe contraceptives (IUD, oral contraceptives, surgical sterilisation and long lasting gestagen.

Exclusion Criteria:

  • Tension type headache more than once/month
  • Other primary headaches
  • Daily medication except contraceptives
  • Drug taken within 4 times the halflife for the specific drug except contraceptives
  • Pregnant or lactating women
  • Exposure to radiation within the last year
  • Headache within the last 24 hours before start of trial
  • Hypertension
  • Hypotension
  • Respiratory or cardiac disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01750723

Danish Headache Center
Copenhagen, Glostrup, Denmark, 2600
Department of Neurology
Copenhagen, Glostrup, Denmark, 2600
Sponsors and Collaborators
Danish Headache Center
Principal Investigator: Nanna Arngrim, MD Danish Headache Center
  More Information

Responsible Party: Nanna Arngrim, MD, medical doctor, Danish Headache Center Identifier: NCT01750723     History of Changes
Other Study ID Numbers: H-3-2012-137
Study First Received: December 11, 2012
Last Updated: July 8, 2013

Keywords provided by Nanna Arngrim, Danish Headache Center:

Additional relevant MeSH terms:
Headache Disorders, Primary
Headache Disorders
Migraine Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Carbonic Anhydrase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Physiological Effects of Drugs processed this record on September 19, 2017